Suppr超能文献

癌抗原125:开端的结束。

CA 125: the end of the beginning.

作者信息

Hovig E, Rye P D, Warren D J, Nustad K

机构信息

Central Laboratory, Norwegian Radium Hospital, Oslo, Norway.

出版信息

Tumour Biol. 2001 Nov-Dec;22(6):345-7. doi: 10.1159/000050637.

Abstract

CA 125, a high-molecular-weight mucin, was first defined in 1981 by the monoclonal antibody OC125. Until recently, it has defied many attempts to purify it from a variety of sources, although many research groups have successfully raised antibodies that bind to CA 125. Nevertheless, CA 125 has demonstrated its considerable value as a marker in monitoring patients with ovarian cancer. This year, two research groups have succeeded in cloning the high-molecular-weight mucin CA 125. Their findings are summarized and the significance discussed in light of existing data from the human genome.

摘要

CA 125是一种高分子量粘蛋白,于1981年首次由单克隆抗体OC125鉴定。直到最近,尽管许多研究小组已成功制备出与CA 125结合的抗体,但从多种来源纯化CA 125的尝试均未成功。然而,CA 125已证明其作为监测卵巢癌患者的标志物具有重要价值。今年,两个研究小组成功克隆了高分子量粘蛋白CA 125。现将他们的研究结果进行总结,并根据人类基因组的现有数据讨论其意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验